Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is filled with mundane chores, primarily tidying the Pharmalot grounds, but we also hope to catch up on our reading and promenade the official mascot. And what about you? This is a fine time to enjoy the great outdoors, especially if you have been vaccinated. You could touch base with folks not seen in some time. Or simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

A third member of a Food and Drug Administration expert panel has resigned over the agency’s contentious approval of the Biogen (BIIB) Alzheimer’s therapy this week, STAT writes. In a letter to acting FDA Commissioner Janet Woodcock on Thursday, Aaron Kesselheim, who had served on the FDA’s advisory committee for nervous system therapies since 2015, wrote that the approval of the drug, called Aduhelm, “was probably the worst drug approval decision in recent U.S. history.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment